Holen Sie sich die Stockscreener-App
67.40
1.51%
-1.03
Handel nachbörslich:
67.34
-0.06
-0.09%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$68.43
Offen:
$68.61
24-Stunden-Volumen:
7.76M
Relative Volume:
1.36
Marktkapitalisierung:
$26.29B
Einnahmen:
$4.30B
Nettoeinkommen (Verlust:
$571.50M
KGV:
47.18
EPS:
1.4285
Netto-Cashflow:
$570.80M
1W Leistung:
+1.29%
1M Leistung:
+1.61%
6M Leistung:
-20.58%
1J Leistung:
-15.84%
1-Tages-Spanne:
$65.60
$68.89
1-Wochen-Bereich:
$65.19
$70.92
52-Wochen-Spanne:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Vergleichen Sie DXCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
67.40 | 26.69B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
125.92 | 219.41B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.64 | 145.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.54 | 140.43B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.53 | 126.52B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 49.08B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
DexCom (DXCM) Price Target Raised by Bernstein | DXCM Stock News - GuruFocus
Bernstein Adjusts Price Target on DexCom to $86 From $84, Maintains Outperform Rating - MarketScreener
How DexCom Inc. stock compares to growth peersMarket Movement Recap & Low Risk High Reward Ideas - ulpravda.ru
Will DexCom Inc. stock benefit from sector rotationTrade Entry Summary & Reliable Breakout Stock Forecasts - ulpravda.ru
How DexCom Inc. stock performs in weak economyTake Profit & Safe Capital Growth Stock Tips - ulpravda.ru
Dexcom Finishes Off Class Claims Over Sales Growth Statements - Bloomberg Law News
DexCom (DXCM) Stock Trades Down, Here Is Why - Finviz
Why DexCom Inc. stock is rated strong buyTreasury Yields & Reliable Volume Spike Trade Alerts - ulpravda.ru
Published on: 2026-01-08 22:18:15 - ulpravda.ru
Is DexCom Inc. stock a good choice for value investorsVolume Spike & Short-Term Trading Opportunity Alerts - ulpravda.ru
Dexcom CEO Jake Leach Takes the Helm, Presents Future at CES - Medical Product Outsourcing
Dexcom enters next era of continued innovation with Jake Leach as chief executive officer - MarketScreener
Dexcom CEO Jake Leach begins tenure with focus on metabolic health By Investing.com - Investing.com South Africa
Dexcom CEO Jake Leach begins tenure with focus on metabolic health - Investing.com UK
Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer - DexCom Investor Relations
Is DexCom, Inc.'s (NASDAQ:DXCM) Recent Stock Performance Tethered To Its Strong Fundamentals? - 富途牛牛
DexCom Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
UBS (AMUB) DexCom-linked trigger autocallable notes detail coupons and downside risk - Stock Titan
Dexcom Inc. Bets Big on Continuous Glucose Monitoring — and It’s Winning - AD HOC NEWS
Why pension funds invest in DexCom Inc. (DC4) stock2026 world cup usa national team qualification defensive leaders high defensive line knockout prediction preview - ulpravda.ru
DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
How DexCom Inc stock performs in weak economy2025 Performance Recap & AI Enhanced Trading Signals - moha.gov.vn
Dexcom names Jacob Leach as incoming chief executive - MSN
Assessing DexCom (DXCM) Valuation As Shares Lag Over The Past Year - Yahoo Finance
DexCom, Inc.'s (NASDAQ:DXCM) Stock Been Rising: Are Strong Financials Guiding The Market? - Yahoo Finance
Who Owns Dexcom? Top Shareholders and Recent Insider Trades - TIKR.com
DexCom, Inc. $DXCM Shares Sold by Ethic Inc. - Defense World
Dexcom Stock in Focus: Quiet Rally, Mixed Signals and a Data?Driven Bet on Connected Diabetes Care - AD HOC NEWS
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Mobile Health (mHealth) Technologies and Global Markets Report 2025-2030 Featuring Leading CompaniesApple, Samsung, AT&T, Medtronic, Abbott, Koninklijke Philips N.V., and DexcomResearchAndMarkets.com - The AI Journal
DexCom Inc Stock Price Live, Charts & News - The Economic Times
The Truth About DexCom Inc: Why Everyone Is Suddenly Watching DXCM - AD HOC NEWS
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium - TradingView — Track All Markets
DexCom Inc (NASDAQ:DXCM) Embodies the Growth at a Reasonable Price (GARP) Strategy - Chartmill
DexCom (NASDAQ:DXCM) & Avanos Medical (NYSE:AVNS) Head-To-Head Contrast - Defense World
Dexcom Stock Finds Its Range: What The Latest Drift, Data, And Deals Signal For 2026 - AD HOC NEWS
FDA says Dexcom issues correction for Dexcom G6 and G6 Pro software - marketscreener.com
E. Ohman J or Asset Management AB Raises Position in DexCom, Inc. $DXCM - MarketBeat
SWS Partners Purchases 19,073 Shares of DexCom, Inc. $DXCM - MarketBeat
Beacon Investment Advisory Services Inc. Trims Stock Position in DexCom, Inc. $DXCM - Defense World
Class Action Alert: Levi & Korsinsky Reminds DexCom (DXCM) Investors of December 26, 2025 Deadline - ACCESS Newswire
Recover Investment Losses: Class Action Initiated Against DexCom, Inc. (DXCM) - ACCESS Newswire
DexCom, Inc. Sued for Securities Law Violations – Investors - GlobeNewswire
DexCom, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before December 26, 2025 to Discuss Your RightsDXCM - Finviz
DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, - GlobeNewswire
DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds DXCM Investors of the December 26th Deadline for Contacting the Firm - GlobeNewswire Inc.
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DXCM DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts DexCom, Inc. Investors to Participate in the Class Action Lawsuit - ACCESS Newswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Levi & Korsinsky Urges DexCom (DXCM) Shareholders to Act Before Lead Plaintiff Deadline December 26, 2025 - ACCESS Newswire
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.48%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):